title: Etanercept, improved dosage schedules and combinations in the treatment of psoriasis: an update.
abstract: Etanercept, a subcutaneously administered fully human soluble tumor necrosis factor (TNF) receptor, was initially approved for the treatment of psoriasis at a dose of 25 mg twice weekly in repeated 24-week cycles with the possibility to double the dose in the first 12 weeks of the first cycle. During intermittent treatment, patients retain their ability to respond to etanercept. Recently, a new dosing schedule of etanercept 50 mg once weekly was approved, based on a study in which PASI-75 (75% improvement of Psoriasis Area and Severity Index) was achieved by 37% and 71% of patients at week 12 and 24. Another study demonstrated a PASI-75 of 57% and 69% in pediatric psoriasis patients receiving etanercept 0.8 mg/kg (up to 50 mg) once weekly for 12 and 24 weeks respectively, resulting in European approval from age 8. Based on recent clinical trials, the antipsoriatic effect of etanercept can be markedly increased in combination with acitretin, methotrexate or UVB. The combination with acitretin appears attractive because of its non-immunosuppressive and chemopreventive properties. Etanercept-methotrexate combination therapy is well established in rheumatologic patients. From a long-term perspective, the combination of TNF-inhibitors with phototherapy (photocarcinogenesis) or cyclosporine (carcinogenesis, infections) warrants great caution however. Finally, combination with topical calcipotriol-betamethasone ointment may increase the speed of response to TNF-inhibitors in the first 4 weeks of treatment.
authors.affiliation: Department of Dermatology, University Hospital Leuven, Belgium.
authors.forename: Siegfried
authors.initials: S
authors.lastname: Segaert
references.citation: Br J Dermatol. 2005 Jun;152(6):1304-12
references.pmid: 15948997
references.citation: Int J Dermatol. 2008 Feb;47(2):202-4
references.pmid: 18211500
references.citation: Br J Dermatol. 2007 Jan;156(1):138-42
references.pmid: 17199580
references.citation: J Pharmacol Exp Ther. 2002 May;301(2):418-26
references.pmid: 11961039
references.citation: N Engl J Med. 2003 Nov 20;349(21):2014-22
references.pmid: 14627786
references.citation: Gastroenterology. 2001 Nov;121(5):1088-94
references.pmid: 11677200
references.citation: Br J Dermatol. 2008 Jun;158(6):1345-9
references.pmid: 18410408
references.citation: N Engl J Med. 2005 Jan 27;352(4):351-61
references.pmid: 15673801
references.citation: J Clin Invest. 2007 Dec;117(12):3833-45
references.pmid: 17992258
references.citation: Exp Dermatol. 2004 Apr;13(4):193-222
references.pmid: 15086336
references.citation: Proc Natl Acad Sci U S A. 1975 Sep;72(9):3666-70
references.pmid: 1103152
references.citation: Arch Dermatol. 2003 Dec;139(12):1627-32; discussion 1632
references.pmid: 14676082
references.citation: J Am Acad Dermatol. 2004 Mar;50(3):416-30
references.pmid: 14988684
references.citation: J Am Acad Dermatol. 2000 May;42(5 Pt 1):829-30
references.pmid: 10775863
references.citation: J Eur Acad Dermatol Venereol. 2009 Dec;23(12):1374-82
references.pmid: 19563497
references.citation: Nat Med. 1999 Jul;5(7):828-31
references.pmid: 10395330
references.citation: J Drugs Dermatol. 2008 Mar;7(3):245-53
references.pmid: 18380206
references.citation: J Dermatolog Treat. 2006;17(2):86-9
references.pmid: 16766332
references.citation: Br J Dermatol. 1999 Apr;140(4):656-60
references.pmid: 10233316
references.citation: Nature. 1999 Feb 11;397(6719):530-4
references.pmid: 10028970
references.citation: N Engl J Med. 2003 Feb 13;348(7):601-8
references.pmid: 12584368
references.citation: J Am Acad Dermatol. 2006 Mar;54(3 Suppl 2):S101-11
references.pmid: 16488320
references.citation: J Eur Acad Dermatol Venereol. 2006 Sep;20(8):988-98
references.pmid: 16922950
references.citation: JAMA. 2006 May 17;295(19):2275-85
references.pmid: 16705109
references.citation: Clin Infect Dis. 2004 May 1;38(9):1261-5
references.pmid: 15127338
references.citation: N Engl J Med. 2008 Jan 17;358(3):241-51
references.pmid: 18199863
references.citation: Br J Dermatol. 2008 Aug;159(2):460-3
references.pmid: 18547310
references.citation: Arch Dermatol. 2007 Jun;143(6):719-26
references.pmid: 17576937
references.citation: Br J Dermatol. 2008 Nov;159(5):1177-85
references.pmid: 18673365
references.citation: Arthritis Rheum. 2006 Apr;54(4):1063-74
references.pmid: 16572441
references.citation: Int J Immunopathol Pharmacol. 2009 Jan-Mar;22(1):219-25
references.pmid: 19309569
references.citation: Br J Dermatol. 2006 Oct;155(4):808-14
references.pmid: 16965432
references.citation: Int J Dermatol. 2008 May;47(5):514-8
references.pmid: 18412874
references.citation: Br J Dermatol. 2009 Jan;160(1):186-9
references.pmid: 19067710
references.citation: Br J Dermatol. 2008 Aug;159(2):407-12
references.pmid: 18565187
references.citation: Ann Rheum Dis. 2009 Jul;68(7):1177-83
references.pmid: 19019889
references.citation: Acta Derm Venereol. 2008;88(5):495-501
references.pmid: 18779890
references.citation: Ann Rheum Dis. 2008 Feb;67(2):182-8
references.pmid: 17728331
references.citation: Photochem Photobiol. 1998 May;67(5):541-6
references.pmid: 9644008
references.citation: Clin Exp Dermatol. 1994 Sep;19(5):383-7
references.pmid: 7955493
references.citation: J Am Acad Dermatol. 2008 May;58(5):826-50
references.pmid: 18423260
references.citation: J Biol Regul Homeost Agents. 1997 Jul-Sep;11(3):115-8
references.pmid: 9498161
references.citation: J Dermatolog Treat. 2006;17(1):9-17
references.pmid: 16467018
references.citation: Br J Dermatol. 2008 May;158(5):1098-106
references.pmid: 18384440
references.citation: J Invest Dermatol. 1995 Jun;104(6):922-7
references.pmid: 7769259